Steen Helde Hemmingsen

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award.

Aravis AG (Aravis) is an independent venture capital firm, founded in 2001 by Jean-Philippe Tripet and headquartered in Muttenz, Switzerland.

Synendos Therapeutics AG develops molecules for the treatment of anxiety and stress-related disorders. The company was founded by Andrea Chicca, Simon Russell and Jürg Gertsch in April 2019 and is headquartered in Allschwil, Switzerland.

Nuevolution A/S engages in research and experimental development on biotechnology. It produces and commercializes technologies for the manufacture of substances for use in the pharmaceutical industry by screening non-biological polymers and low-molecular substances. The company was founded on May 8, 2001 and is headquartered in Copenhagen, Denmark.

Sensimed SA develops non-invasive soft contact lens-based solutions. It offers solutions to monitor fluctuations in intraocular pressure continuously. The company was founded by Matteo Leonardi and Sacha Cerboni in 2003 and is headquartered in Lausanne, Switzerland.

Isocell SA operates as a holding company with interests in the manufacture of food supplements. It develops proprietary formulation for super-oxyde dismutase. The firm also targets food areas including sodas, sport drinks and dairies with wellness claims. It also engages in the ownership and operations of medical laboratories. The company was founded by Francois Vix on July 9, 2001 and is headquartered in Paris, France.

Union Therapeutics A/S operates as a clinical stage pharmaceutical company which focuses on the treatment of inflammatory skin disease. It also centers in the development of molecules exhibiting immunological and microbiological effects. The company is headquartered in Hellerup, Denmark.

AlchiMedics SA specializes in coating technologies via electrografting. Its products enables covalent adhesion of nano to micrometric polymer-based layers on surfaces. The firm designs, develops and implements electro-grafting technology for implantable biomedical applications. The company was founded in 2007 and is headquartered in Grenoble, France.

Auriga Partners SA (Auriga) is an independent, management-owned venture capital firm which was founded by Patrick Bamas, Jacques Chatain and Bernard Daugeras in 1998. Headquartered in Paris, the firm's core activity is enterprise creation. In addition to providing a network of contacts capable of accelerating internationalization, and furthering strategic partnerships and business deals, Auriga manages several seed and early-stage funds specializing in information technology and life sciences.

AntibioTx ApS develops and manufactures pharmaceutical products. The private company is based in Kongens Lyngby, Denmark.

Albumedix A/S is a Danish biotechnology company. The private company is based in Copenhagen, Denmark.

Novozymes Biopharma DK A/S engages in the wholesale of pharmaceuticals and medical article. The firm operates and invests in research, development, production, and trade in biological solutions, including pharmaceuticals, and biotechnology products and processes.The company was founded on May 29, 2006 and is headquartered in Bagsvaerd, Denmark.

Novozymes BioloAg A/S provides research and development for biotechnology products and processes. It participates in The BioAg Alliance to commercialize BioAg assets and competencies within microbial research, development, and production. The company was founded on October 22, 2007 and is headquartered in Bagsvaerd, Denmark.

Unibio International Plc is a leading British sustainable protein company that specializes in producing single-cell protein for animal feed. The company is based in London, UK, and David Henstrom has been the CEO since 2021. The company has won several awards for its environmentally friendly practices, including the "Kalundborg Business Council's Green Environment and Climate Award." Unibio has participated in various exhibitions and conferences worldwide, including the "Forum for Innovations in Agriculture" in 2018 and the "Deutsche Messe Hannover" in 2018.

Part of Phytera, Inc., Auda Pharmaceuticals ApS provides proprietary combinatorial chemistry technologies. Auda Pharmaceuticals was acquired by Phytera, Inc. from Danish Development Finance Corp on March 17, 1997.

PNA-Diagnostics A/S manufactures medical diagnostic equipment. The firm is a subsidiary of Applera Corp. The company is headquartered in Copenhagen, Denmark

Part of Perrigo Co. Plc, Quadrant Healthcare Plc is a British company that researches, develops, and formulates drugs. The company is based in Cambridge, UK. Quadrant Healthcare was acquired by Elan Europe Ltd. on January 11, 2001 for $69.60 million.

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

Alentis Therapeutics AG develops novel medications to treat advanced liver diseases and cancers. The company was founded by Neil Goldsmith on March 1, 2019 and is headquartered in Basel, Switzerland.

Double Bioventures Ltd. is a British company founded in 2018 that builds non-traditional life-science companies in non-traditional ways. The private company is based in London, UK. The company focuses on identifying opportunities outside core therapeutics and developing robust business models for such businesses. The company aims to help life-science ventures play a wider role in meeting the challenges of the modern world.

Sundew ApS targets water-borne pests and diseases. The company is based in Copenhagen, Denmark. and has subsidiaries in Ireland. The Danish company was founded in 2018 by Neil Goldsmith, Jørgen Hansen, Andy Gardiner. Giovanni Salerno has been the CEO of the company since 2021.